![](https://fbexternal-a.akamaihd.net/safe_image.php?d=AQDkukGe3sw-ovL4&w=470&h=246&url=https%3A%2F%2Fi.guim.co.uk%2Fimg%2Fmedia%2Fdaea80129baef4a7a249fa84251e47c2e0a1b03c%2F0_0_2973_1784%2Fmaster%2F2973.jpg%3Fw%3D1200%26q%3D85%26auto%3Dformat%26sharp%3D10%26s%3D0f107ded5673a3bee9d93db0bd465496&cfs=1&upscale=1&sx=0&sy=44&sw=1200&sh=628&ext=png2jpg)
Former president given pembrolizumab, one of the most promising new drugs in the treatment of cancer
www.theguardian.com
A “checkpoint inhibitor” is “curing” former US president Jimmy Carter of his cancer.
The 3 hotcakes in cancer immunotherapy currently are Keytruda (Pembrolizumab), Opdivo (Nivolumab) and Yervoy (Ipilimumab). The latter blocks CTLA4 (cytotoxic T-lymphocyte-associated protein) on activated T-cells, thereby preventing winding-down of their fight against enemy cells (germs, cancer). The first 2 block PD-1 (programmed cell death), preventing activated T-cells from committing suicide after they have decimated the “enemies”. The downside to these anti-cancer boosters is that they may trigger autoimmune diseases. In this way, oncologists generate work for rheumatologists!